[{"id":"722e7e39-2b2e-4e81-be40-58b1e321be96","acronym":"","url":"https://clinicaltrials.gov/study/NCT06043713","created_at":"2023-09-21T15:10:30.740Z","updated_at":"2025-02-25T13:41:44.027Z","phase":"Phase 1","brief_title":"Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations","source_id_and_acronym":"NCT06043713","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK","pipe":" | ","alterations":" KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion","tags":["HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 12/15/2023","start_date":" 12/15/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 02/09/2026","study_completion_date":" 02/09/2026","last_update_posted":"2025-02-21"},{"id":"1387da34-72f6-46cd-8db5-48bc41fc9fe6","acronym":"AFNT211-22-101","url":"https://clinicaltrials.gov/study/NCT06105021","created_at":"2023-10-27T17:14:07.431Z","updated_at":"2025-02-25T13:55:42.802Z","phase":"Phase 1/2","brief_title":"Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor","source_id_and_acronym":"NCT06105021 - AFNT211-22-101","lead_sponsor":"Affini-T Therapeutics, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFNT-211"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/06/2024","start_date":" 03/06/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2025-02-20"},{"id":"c588db17-efc8-49b9-af67-a28b72dc4313","acronym":"","url":"https://clinicaltrials.gov/study/NCT06096974","created_at":"2023-10-24T15:13:42.150Z","updated_at":"2024-07-02T16:35:31.995Z","phase":"Phase 1","brief_title":"Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS","source_id_and_acronym":"NCT06096974","lead_sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","biomarkers":" PD-L1 • KRAS • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • HRAS mutation","tags":["PD-L1 • KRAS • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e YL-17231"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2023-10-24"},{"id":"77602bae-c8cf-42ee-afb1-9b4462427822","acronym":"","url":"https://clinicaltrials.gov/study/NCT06078800","created_at":"2023-10-12T22:13:54.839Z","updated_at":"2024-07-02T16:35:33.764Z","phase":"Phase 1","brief_title":"A Study of YL-17231 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT06078800","lead_sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","biomarkers":" PD-L1 • KRAS • MSI","pipe":" | ","alterations":" MSI-H/dMMR • KRAS wild-type • RAS wild-type","tags":["PD-L1 • KRAS • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e YL-17231"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 09/28/2023","start_date":" 09/28/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-10-12"},{"id":"5cfcbe7d-4d03-4117-95be-9b8d7199f4ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04146298","created_at":"2021-01-18T20:14:11.889Z","updated_at":"2024-07-02T16:35:38.229Z","phase":"Phase 1/2","brief_title":"Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer","source_id_and_acronym":"NCT04146298","lead_sponsor":"Changhai Hospital","biomarkers":" KRAS • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V • KRAS expression","tags":["KRAS • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V • KRAS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-09-01"},{"id":"41426191-e861-4497-bd26-22264d4bdb1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05933668","created_at":"2023-07-06T16:10:24.750Z","updated_at":"2024-07-02T16:35:43.789Z","phase":"Phase 1","brief_title":"Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Solid Tumor","source_id_and_acronym":"NCT05933668","lead_sponsor":"Peking University","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS G12V • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12V • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • oxaliplatin • YK0901"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2023-07-06"}]